
XRN Stock Forecast & Price Target
XRN Analyst Ratings
Bulls say
Chiron Real Estate is supported by a compelling, self-funded transformation from lower-growth medical office assets into senior housing operating properties, a segment with strong demographic tailwinds from the aging Baby Boomer cohort and constrained new supply. Its 3Q26 results showed diluted Core FFO of $0.75 per share versus $0.84 estimated, while same-property cash NOI still rose 1.6% year over year and the outpatient medical portfolio remained 93.6% leased with a 74.4% NOI margin, underscoring durable underlying cash generation. Management has also strengthened liquidity and reduced risk with net debt to adjusted EBITDAre improving to 6.0x, no debt maturities until 2028, and executed asset sales and SHOP acquisitions that should support higher long-term growth and a narrower valuation discount as lease-up progresses.
Bears say
Chiron Real Estate is facing a fundamental growth stall as higher rates since 2022 compressed acquisition spreads, reduced external growth, and left its medical office portfolio with only 2.1% blended rent escalators and a 4.4-year WALT, making organic expansion modest. Management’s shift from OMF into SHOP at a roughly 50 bps negative initial investment yield spread, along with slower lease-up at The Riviera and Pinnacle, has driven down normalized FAD estimates to $2.64 and $1.16 for 2026 and 2027, with $2.40 per share initiated for 2028. Despite near-full occupancy and a durable healthcare tenant base, the company’s small scale, limited $3mm-$4mm daily trading liquidity, and concentration in a few states heighten execution and investor-access risks.
This aggregate rating is based on analysts' research of Chiron Real Estate Inc and is not a guaranteed prediction by Public.com or investment advice.
XRN Analyst Forecast & Price Prediction
Start investing in XRN
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Chiron Real Estate Inc (XRN) Forecast
XRN Analyst Forecast & Price Prediction
Start investing in XRN
Order type
Buy in
Order amount
Est. shares
0 shares